Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses early data on ARV-110, an androgen receptor proteolysis–targeting chimera degrader, demonstrating antitumor activity in metastatic castration-resistant prostate cancer after treatment with enzalutamide and abiraterone (Abstract 3500).
Douglas B. Johnson, MD, of Vanderbilt University Medical Center, discusses three important melanoma abstracts: the need for more than two doses of nivolumab plus ipilimumab in combination immunotherapy; antitumor activity for low-dose ipilimumab with pembrolizumab after disease progression on PD-1 antibodies; and ipilimumab alone or in combination with anti–PD-1 therapy for metastatic disease resistant to PD-1 monotherapy (Abstracts 10003, 10004, and 10005).
Nikhil C. Munshi, MD, of Dana-Farber Cancer Institute, discusses initial results from the KarMMa tria, showing that idecabtagene vicleucel, a B-cell maturation antigen-targeted CAR T-cell therapy, demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma. Efficacy and safety data support a favorable clinical benefit-risk profile across the target dose range (Abstract 8503).
Farhad Ravandi-Kashani, MD, of The University of Texas MD Anderson Cancer Center, discusses updates from a phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule. It showed early evidence of an acceptable safety profile, drug tolerability, and antileukemic activity, supporting further dose escalation in patients with acute myeloid leukemia (Abstract 7508).
Alberto F. Sobrero, MD, of the Ospedale San Martino, discusses final results of the IDEA study, which supported the use of 3 months of adjuvant CAPOX, vs 6 months, for most patients with stage III colon cancer. The shorter treatment duration reduced toxicity, inconvenience, and cost (Abstract 4004).
Christopher Nutting, MD, PhD, of the Royal Marsden Hospital and Institute of Cancer Research, discusses phase III results from the first study to demonstrate the functional benefit of swallow-sparing intensity-modulated radiotherapy in oro- and hypopharyngeal cancers (Abstract 6508).
